UK and US Stem Cell Banks team up to share expertise
Plan to drive forward stem cell research
The UK and UMASS Stem Cell Banks have signed a Memorandum of Understanding (MOU) that will outline plans for cooperation in a variety of stem cell areas including the delivery of stem cell lines for clinical use.
The agreement outlines plans for the two stem cell banks to work together to ensure that best practice and high standards in stem cell banking are employed at both sites. They will also develop international training events for scientists involved in stem cell research.
Stem cells are the body's 'master cells', with the potential to become many different types of tissue. It is hoped that stem cell treatments may be used in future to help people with Parkinson's disease, diabetes or multiple sclerosis by repairing and replacing diseased and damaged body tissue.
The UK Stem Cell Bank, funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council, is a repository for human cell lines, derived from stem cells. It also holds new and existing adult, foetal and embryonic stem cell lines. Stem cell lines are provided only to accredited researchers to ensure the safe and ethical development of any potential stem cell therapy.
Dr Stephen Inglis, director of HPA's NIBSC said: ‘International co-operation is vital in this fast moving field and we expect that the partnership will accelerate the development of important new therapies, as well as keeping the UK at the forefront of stem cell research.’
Joseph Laning, senior director of the Human Stem Cell Bank and Registry at UMASS Medical School, added: ‘Both banks share common goals and needs. Working in concert allows us to develop strategies that will shape stem cell production, characterisation, banking and distribution in a dynamic field. Each bank brings its own unique attributes to bear in a way that will enhance our influence in the field.’
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents